Viveon Health Acquisition Corp. financial data

Industry
Pharmaceutical Preparations
Location
3480 Peachtree Road Ne, 2 Nd Floor Suite #112, Atlanta, GA
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2023 - Jun 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.51 % -95.5%
Debt-to-equity -158 % -51.3%
Return On Equity -7.71 % -139%
Return On Assets 2.8 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.66M shares
Common Stock, Shares, Outstanding 5.03M shares 0%
Entity Public Float 103M USD
Common Stock, Value, Issued 503 USD 0%
Weighted Average Number of Shares Outstanding, Basic 5.87M shares -73.3%
Weighted Average Number of Shares Outstanding, Diluted 5.87M shares -73.3%

Income Statement

Label TTM Value / Value Unit Change %
Costs and Expenses 500K USD
Operating Income (Loss) -1.93M USD +60.9%
Nonoperating Income (Expense) 3.16M USD +40.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 163K USD
Income Tax Expense (Benefit) -99.5K USD
Net Income (Loss) Attributable to Parent 1.27M USD
Earnings Per Share, Basic 0.06 USD/shares
Earnings Per Share, Diluted 0.06 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 77.9K USD -96.3%
Assets, Current 82.9K USD -96%
Deferred Income Tax Assets, Net 139K USD
Assets 20.6M USD -61.7%
Accounts Payable, Current 224K USD -4.98%
Accrued Liabilities, Current 2.42M USD -10.3%
Liabilities, Current 7.84M USD +138%
Liabilities 17M USD -2.66%
Retained Earnings (Accumulated Deficit) -15.9M USD -4.07%
Stockholders' Equity Attributable to Parent -15.9M USD -4.07%
Liabilities and Equity 20.6M USD -61.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -174K USD +59.9%
Net Cash Provided by (Used in) Financing Activities -33.5M USD +77.6%
Net Cash Provided by (Used in) Investing Activities 33.7M USD -77.8%
Common Stock, Shares Authorized 60M shares 0%
Common Stock, Shares, Issued 5.03M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 58K USD -96.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 19.8K USD -95%
Deferred Tax Assets, Valuation Allowance 1.86M USD +124%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure
Deferred Tax Assets, Gross 1.9M USD +129%
Deferred Tax Assets, Operating Loss Carryforwards 704K USD +1694%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 766K USD
Additional Paid in Capital 157K USD -95.1%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 39.3K USD
Interest Expense 3.56M USD -91.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%